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Background: Nerve injury-induced neuropathic pain is a major health problem worldwide. Notch signaling is a
highly conserved pathway in evolution, which has an important role in synaptic plasticity and inflammation in
central nervous system. The present study was designed to investigate the potential role of notch signaling in the
development of neuropathic pain.
Methods: The neuropathic pain was induced by spared nerve injury (SNI) in rats. The activation of notch signaling
in the lumbar spinal dorsal horn was measured. DAPT, an inhibitor of notch signaling, was intrathecally (i.t.)
administered before SNI or after appearance of pain sensitivity. Moreover, Jagged-1 (JAG-1) peptide, a ligand of
notch signaling, was i.t. administered to normal rats. The mechanical allodynia was assessed by von Frey test.
Results: Here, we found that DAPT administered 0.5 h before SNI operation could significantly prevent the
decrease of mechanical paw withdrawal threshold (PWT) for more than 4 weeks (P < 0.05 vs. SNI group). DAPT
administered after appearance of pain sensitivity could also significantly reverse the decrease of mechanical PWT in
a dose-dependent manner (P < 0.05). In addition, administration of Jagged-1 (JAG-1) peptide significantly decreased
the mechanical PWT of normal rats in a dose-dependent manner (P < 0.05).
Conclusions: Therefore, notch signaling activation might contribute to the development of neuropathic pain. This
study might provide a new therapeutic target for neuropathic pain.
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Neuropathic pain is a chronic pain resulting from dys-
function or damage of the nerve fibers of peripheral or
central nervous system (CNS) [1]. The mechanism is
complicated and unclear, which is associated with hyper-
excitability in the affected dorsal root ganglion (DRG)
neurons, atrophic changes and a switch in neurotrans-
mitter phenotype in the central afferent terminal, aber-
rant myelination, alterations in synaptic plasticity and
excitatory and inhibitory mechanisms in spinal cord, and
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unless otherwise stated.brain input to spinal cord [1-7]. Although there is sig-
nificant improvement in treatment, neuropathic pain
frequently remains unresponsive to all treatment modal-
ities [8]. Notch signaling is a highly conserved pathway
in evolution, which often regulates cell-fate decisions in
developing nervous system and has an important role in
synaptic plasticity in adult CNS [9-12]. Numerous stud-
ies have demonstrated that notch signaling is crucial for
many biological processes such as development, immun-
ology, inflammation, tumor formation and memory
[11,13-17]. Recent studies show that notch signaling ac-
tivation might contribute to neuronal death, inhibition
of neurite growth, more dendritic branching, generation
and activation of microglial cells and astrocytes, differen-
tiation of oligodendrocyte progenitors and demyelination
in both peripheral nervous system and CNS [9,18-24].
Moreover, notch signaling controls the choice between
excitatory and inhibitory cell fates in developing spinal
cord, and its activation can promote the generation ofs is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tors [25]. In addition, the expression and activity of notch
signaling are significantly increased after nerve injury [26].
Ligands such as Delta and Jagged bind to Notch receptors,
resulting in proteolytic cleavage of Notch into two sec-
tions: an extracellular domain and a transmembrane do-
main. The latter cleavage is completed by the γ-secretase
enzyme and ADAM, which results in the release of a
Notch intracellular domain (NICD).
Therefore, we hypothesized that notch signaling activa-
tion might contribute to the development of neuropathic
pain. In the present study, we firstly investigated the acti-
vation of notch signaling in the lumbar spinal dorsal horn.
Then, the effects of a notch signaling inhibitor DAPT ad-
ministered at different times on the mechanical allodynia
were measured in a rat model of spared nerve injury
(SNI)-induced neuropathic pain. Last, we studied the ef-
fects of a notch signaling activator Jagged-1 (JAG-1) pep-
tide on the mechanical allodynia in normal rats. This
study may provide a new therapeutic target for neuro-
pathic pain.Methods
Animals
All experiments were performed on adult male Sprague–
Dawley rats weighing 200–250 g (Laboratory Animal Cen-
ter of the Tianjin Medical University, Xi’an, China). The
animals were housed in plastic boxes at 22–26°C with
food and water available ad libitum. A 12:12 h light/dark
cycle with lights on at 8:00 was maintained and testing
was done between 9:00 and 18:00. Prior to experimental
manipulation, animals were allowed to acclimate to the
housing facilities and were handled daily at least for 3 d.
All experimental protocols and animal handling proce-
dures were approved by the Tianjin Medical University
Animal Care and Use Committee and were in accordance
with the guidelines for the ethical treatment of animals
established by the International Association for the Study
of Pain. All efforts were made to minimize animal suffer-
ing and to reduce the number of animals used.Intrathecal catheterization and drug delivery
A permanent intrathecal (i.t.) catheter (PE-10 polyethylene
tube, BD Biosciences, Franklin Lakes, NJ) was inserted
through the gap between T3 ~ 4 vertebrae and extended
slowly to the subarachniod space of lumbar enlargement
(L4 and L5 segments) under pentobarbital sodium
anesthesia [40 mg/kg, intraperitoneal (i.p.)] [27]. The cath-
eter was filled with sterile saline (approximately 4 μL), and
the outer end was plugged. All animals appeared to be free
of infection through gross inspection. The cannulated ani-
mals were allowed to recover for 4 days. Motoric integrity
was assessed in all animals using the righting reflex andinclined plane test. Animals showing any neurological def-
icits were excluded from the following experiment.
Drugs were injected over a period of 1 min via the
catheter at a volume of 10 μL, followed by 5 μL sterile
saline for flushing. DAPT (Sigma-Aldrich, St. Louis,
MO, USA) and JAG-1 peptide (CDDYYYGFGCNKFC
RPR) (AnaSpec, San Jose, CA, USA), as a potent inhibi-
tor and activator of notch signaling, respectively, were
both freshly dissolved in dimethyl sulfoxide (DMSO) at
a concentration of DAPT (25, 50 or 100 μM) and at a
concentration of JAG‑1 peptide (1, 10 or 100 μM) [19].
The DMSO or scrambled peptide (SC)-JAG-1 (RCGPD
CFDNYGRYKYCF) (AnaSpec, San Jose, CA, USA) was
used as a control. The location of the distal end of this
catheter was verified at the end of each experiment by
injection of pontamine sky blue via the catheter.
Spared nerve injury (SNI) model
The neuropathic pain was induced by left SNI model as
previously described [28]. Briefly, under pentobarbital
sodium anesthesia, an incision was made on the lateral
thigh and the underlying muscle was separated to expose
sciatic nerve. The three terminal branches of sciatic
nerve (tibial, common peroneal and sural nerves) were
carefully separated. After separation, the tibial and com-
mon peroneal nerves were tightly ligated with 5.0 silk,
and then 2–3 mm of the nerves distal to the ligation was
removed. The muscle and skin incisions were then
closed separately. Sham operation was performed identi-
cally without the passage of ligatures or transection of
the nerves.
Assessment of notch signaling activity
The activation of notch signaling was measured by
western-blot of NICD. The lumbar spinal dorsal horn
tissues were harvested, sonicated/homogenized and
centrifuged. The protein was extracted from the above
preparations, and loaded and separated on a 10% (w/v)
SDS-polyacrylamide gel. After transfer, blots were incu-
bated overnight at 4°C with separately with NICD
(1:1000; Abcam, London, UK) and beta-actin (1:10000;
Chemicon, Temecula, CA, USA) primary antibodies.
The membrane was washed and primary antibodies
were detected with secondary antibody conjugated to
horseradish peroxidase for 1 h at room temperature.
Blots were visualized using enhanced chemilumines-
cence (ECL; Roche, Basel, Switzerland).
Assessment of mechanical allodynia
The mechanical allodynia was assessed by von Frey test
as previous described [29]. Mechanical allodynia of rats
was determined by paw withdrawal threshold (PWT) in
response to mechanical stimuli produced by using a cali-
brated series of von Frey filaments (Stoelting, Chicago,
Figure 1 Changes in expression of NICD in the dorsal horn of
lumbar spinal cord in control and SNI model rats. Immunoblotting
showed the expression of NICD in the dorsal horn of lumbar spinal
cord. NICD increased from 3 days to 28 days after nerve injury (SNI
model). NICD: notch intracellular domain; SNI: spared nerve injury.
Figure 2 DAPT (an inhibitor of notch signaling pathway)
administered before appearance of pain sensitivity significantly
prevents the development of mechanical allodynia in SNI-
induced neuropathic pain. A single administration of DAPT (50 μM,
10 μL, i.t.) was 0.5 h before SNI operation. The mechanical mechanical
paw withdrawal threshold (PWT) was measured at 24 h before
(baseline) as well as 7 d, 14 d, 21 d and 28 d after SNI or Sham
operation. The data represent mean ± SD (n = 6 per group). *P < 0.05
versus Sham group; †P < 0.05 versus SNI group. SNI: spared nerve
injury; BL: baseline; g: gram; d: day.
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ation for at least 30 min before stimulation was initiated.
During the test, the rats were placed on a metal mesh
floor covered with the same plastic box and von Frey fila-
ments were applied from the underneath of metal mesh
floor to the lateral plantar surface of the paw (the area in-
nervated by sural nerve). Each filament was presented per-
pendicularly against the paw, with sufficient force to cause
slight bending, and held 2–3 s. The filament was applied
only when the rat was stationary and standing on all four
paws. A withdrawal response was considered valid only if
the hindpaw was completely removed from the custom-
ized platform. Lifting of the paw due to normal locomotor
behavior was ignored. The monofilaments were applied
with increasing force until the rat withdrew the paw. Each
hair was applied 10 times at 5 s intervals. The bending
force value of the von Frey filament that caused a 50% oc-
currence of paw withdrawal reflex by 10 times stimuli was
expressed as the PWT. After the threshold was deter-
mined for the left hindpaw, the same testing procedure
was repeated on the other hindpaw at 5 min interval. Sec-
ond and third testing trials were run for both hindpaws,
respectively. If the withdrawal threshold in the second or
third trial did not match the withdrawal threshold of the
previous testing trial in a given hindpaw, the next large
hair in the series was tested. This was done until the with-
drawal threshold in the three successive trials matched.
To avoid inter-experimenter differences and subjective
bias, all the behavioral observations were performed by
one who was blind to the treatment.
Statistical analysis
Data are expressed as mean ± standard deviation (SD). Stat-
istical comparisons between groups were done using uni-
variate ANOVA or ANOVA for repeated measurements.
The statistical analysis was performed with SPSS 16.0 soft-
ware (SPSS Inc, Chicago, IL). A P value of less than 0.05
was considered statistically significant for all tests.
Results
Notch signaling is activated after SNI operation
In this study, we firstly investigated the notch signaling
activity at different time points after SNI operation. This
present study showed that NICD expression in the dor-
sal horn of lumbar spinal cord was markedly increased
until 28 days following peripheral nerve injury (Figure 1).
This result suggests that notch signaling is activated dur-
ing the development of neuropathic pain.
Administration of DAPT before SNI operation significantly
prevents the development of mechanical allodynia in
neuropathic pain
In the present study, we then investigated the effects of
notch signaling pathway inhibitor DAPT pretreatmenton mechanical allodynia in a rat model of SNI-induced
neuropathic pain. In this experiment, the mechanical
allodynia in all animals was measured at 24 h before
(baseline) as well as 7 d, 14 d, 21d and 28 d after SNI or
sham operation. The SNI-challenged animals developed
a marked hypersensitivity to innocuous mechanical
stimulation of the lateral surface of the hindpaw (sural
nerve skin area) (Figure 2). The hindpaw contralateral to
the operation was tested over the whole period and did
not demonstrate any statistically significant change in
mechanical PWT from pre-operation baseline (data not
shown). The mechanical PWT from 7 d to 28 d after
SNI operation decreased significantly (Figure 2, P < 0.05
vs. Sham group, n = 6 per group). A single administra-
tion of DAPT (50 μM, 10 μL, i.t.) 0.5 h before SNI oper-
ation significantly improved the mechanical PWT for
more than 28 d after the operation (Figure 2, P < 0.05 vs.
SNI group, n = 6 per group). In addition, we found that
Figure 3 Administration of DAPT after appearance of pain
sensitivity significantly reverses the mechanical allodynia in
SNI-induced neuropathic pain. (A) DAPT (50 μM, 10 μL) or DMSO
was once administrated after appearance of mechanical allodynia
induced by SNI. The mechanical PWT was measured before SNI
operation (baseline), before (0 h) as well as 3 h, 6 h, 12 h, 24 h, 36 h,
48 h, 72 h and 96 h after DAPT or DMSO administration. The data
represent mean ± SD (n = 6 per group). *P < 0.05 versus SNI group. (B)
Different doses of DAPT (25, 50 and 100 μM) or DMSO were
administered after the appearance of mechanical allodynia. Mechanical
PWT was measured prior to SNI surgery (BL), prior to administration
(0 h) and 24 h following DAPT or DMSO administration. The data
represent mean ± SD (n = 6 per group). *P < 0.05 versus DMSO group;
†P < 0.05 versus DAPT 25 μM group; ‡P < 0.05 versus DAPT 100 μM
group. SNI: spared nerve injury; BL: baseline; g: gram; d: day, h: hour.
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PWT of normal rats (data not shown). This result sug-
gests that early inhibition of notch signaling can prevent
the development of mechanical allodynia in neuropathic
pain.
Administration of DAPT after appearance of pain
sensitivity significantly reverses the mechanical allodynia
in neuropathic pain
We then investigated the effects of notch signaling pathway
inhibitor DAPT posttreatment on mechanical allodynia in
SNI-induced neuropathic pain. In the preliminary experi-
ment, we found that the animals developed significant
mechanical allodynia 3 d after SNI operation (data not
shown). A single administration of DAPT (50 μM, 10 μL, i.
t.) after appearance of pain sensitivity (80 h after SNI oper-
ation) significantly increased the mechanical PWT from
3 h to 72 h after DAPT administration (Figure 3A, P < 0.05
vs. SNI group, n = 6 per group). Moreover, different con-
centrations of DAPT (25, 50 and 100 μM) were adminis-
tered after the appearance of pain sensitivity, and the
mechanical PWT was evaluated 24 h after DAPT adminis-
tration. As shown in Figure 3B, administration of DAPT
dose‑dependently increased the mechanical PWT of
neuropathic pain rats (P < 0.05). These results suggest that
late inhibition of notch signaling pathway can also reverse
the mechanical allodynia of neuropathic pain in a dose-
dependent manner.
Administration of Jagged-1 peptide, a ligand of notch
signaling pathway, can induce neuropathic pain-like
behavior in normal rats
To further investigate the role of notch signaling in neuro-
pathic pain, the JAG-1 peptide, a ligand of notch signaling
pathway, were i.t. administered of 1 μM, 10 μM, 100 μM
to normal animals, and the mechanical PWT was mea-
sured 3 h, 6 h, 12 h, 24 h, 36 h, and 48 h after JAG-1 ad-
ministration. The SC-JAG-1 peptide was administered as
a negative control. As shown in Figure 4, a single adminis-
tration of JAG-1 peptide dose-dependently decreased the
mechanical PWT of normal animals from 3 h to 36 h
when compared with SC-JAG-1 peptide group (P < 0.05,
n = 6 per group). The decreased PWT after the injection
of JAG-1 peptide was restored 48 h later. The results fur-
ther suggest that activation of notch signaling contributes
to the development of neuropathic pain.
Discussion
In the present study, we firstly found that notch signal-
ing in dorsal horn of lumbar spinal cord was activated
during the development of neuropathic pain. Early in-
hibition of notch signaling can prevent the development
of SNI-induced neuropathic pain. Late inhibition of
notch signaling can reverse the mechanical allodynia ofneuropathic pain. Furthermore, activation of notch sig-
naling can induce the mechanical allodynia of normal
animals. Therefore, notch signaling activation might be
critical to the development of neuropathic pain.
Injury in nervous system may result in chronic neuro-
pathic pain characterized by increased sensitivity to
painful stimuli (hyperalgesia), the perception of innocu-
ous stimuli as painful (allodynia) and spontaneous pain
[2,8]. It is well known that a characteristic symptom of
neuropathic pain is mechanical allodynia [8]. The SNI
model has proved to be robust, with substantial and pro-
longed changes in mechanical sensitivity that closely
mimic many features of clinical neuropathic pain
[28,29]. The model may provide a useful tool for identi-
fying the underlying mechanisms involved in the devel-
opment of neuropathic pain and as an additional screen
Figure 4 Administration of Jagged-1 peptide, a ligand of notch
signaling pathway, can induce neuropathic pain-like behavior
in normal rats. The Jagged-1 (JAG-1) peptide (1, 10 and 100 μM) or
control scrambled peptide (SC)-JAG-1 were i.t. administered to
normal rats. The mechanical PWT was measured before (baseline) as
well as 3 h, 6 h, 12 h, 24 h, 36 h and 48 h after JAG-1 or SC-JAG-1
administration. The data represent mean ± SD (n = 6 per group).
*P < 0.05 versus SC-JAG-1 group, †P < 0.05 versus JAG‑1 1 μM group;
‡P < 0.05 versus JAG‑1 10 μM group. BL: baseline; g: gram; h: hour.
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found that all the animals developed significant mechan-
ical allodynia in SNI-induced neuropathic pain, which is
consistent with other studies [28,29]. Many potential
mechanisms have been studied which may contribute to
the pathogenesis of neuropathic pain. It has been re-
ported that multiple mechanisms at multiple sites may
operate either alone or together or at different time
courses to produce the complex clinical characteristics
[8]. These include changes in terminal and peripheral
sensitization, phenotypic switches and excitability of in-
jured axons, hyperexcitability in the affected DRG neu-
rons, aberrant myelination (splitting, detachment and
loss of myelin), synaptic plasticity in spinal cord, loss of
inhibitory interneurons and modifications of brain stem
input to spinal cord, and so on [1-7]. Alterations in the
balance of number and/or transmission properties of
these excitatory and inhibitory interneurons are thought
to be major contributing factors for chronic sensory
neuropathies such as hyperalgesia and allodynia [30,31].
In addition, sensory information from the periphery is
integrated and transduced by excitatory and inhibitory
interneurons in the spinal dorsal horn. However, the key
mechanisms that control the induction and maintenance
of neuropathic pain remain unclear.
Notch is a cell-surface receptor that regulates cell-fate
decisions in developing nervous system and has import-
ant roles in synaptic plasticity in adult CNS [9-11]. Bind-
ing of ligands such as Delta and Jagged results in
proteolytic cleavages of notch: first in an extracellular
domain and then in a transmembrane domain [13,14].
The latter cleavage is accomplished by the γ-secretase
enzyme complex, resulting in the release of a notch
intracellular domain (NICD) that translocates into thenucleus, where it regulates transcription [13,14]. All of
the different components necessary for notch signaling,
such as ligands, receptors, and enzymes involved in
notch receptor cleavage, are expressed in the adult CNS
as well as increase significantly after nerve injury and
participate in its reparation [11,26]. Notch signaling is a
highly conserved pathway in evolution, which is crucial
for many biological processes such as development,
immunology, inflammation, vasculogenesis, tumor for-
mation, and learning and memory [11,13-17]. Recent
findings suggest notch signaling activation can contrib-
ute to generation and activation of microglial cells and
astrocytes, inhibition of neurite growth, more dendritic
branching, differentiation of oligodendrocyte progenitors
and demyelination in both peripheral nervous system
and CNS [9,18-24]. Moreover, notch signaling pathway
controls the choice between excitatory and inhibitory
cell fates in the developing spinal cord, and its activation
can promote the generation of excitatory neurons from
the sensory interneuron progenitors [25]. To investigate
the roles of notch signaling in neuropathic pain, a
gamma-secretase enzyme (a key enzyme of notch signal-
ing pathway) inhibitor DAPT was i.t. administered be-
fore or after appearance of pain sensitivity in the rat
model of SNI-induced neuropathic pain. The results
showed that early or late inhibition of notch signaling
could prevent or reverse the mechanical allodynia of rats
with neuropathic pain in a dose-dependent manner. In
addition, administration of JAG-1 peptide (a ligand of
notch signaling pathway) could induce the mechanical
allodynia in normal rats in a dose-dependent manner.
These results suggest that notch signaling activation
contributes to the development of neuropathic pain.
The notch family includes 4 receptors with different
functions, as indicated by the phenotypes of various
notch transgenic mouse lines. These 4 receptors are
expressed unequally in various cell types. Notch recep-
tors and ligands have variable expression in various cell
types. The notch signaling in the sciatic nerve, spinal
dorsal horn and DRG neurons is markedly increased fol-
lowing peripheral nerve injury. Therefore, the notch sig-
naling in neurons should have an important role in the
development of neuropathic pain. DAPT is a non-
specific inhibitor of notch receptors. Therefore the study
does not specify which notch receptor(s) are involved in
allodynia. Moreover, Jagged 1 is also a non-specific lig-
and of Notch receptors. Moreover, Jagged 1 may have
different affinities for different notch receptors, depend-
ing on cellular context and post-translational modifica-
tions. Also, the extracellular Jag1 peptide will activate
notch signaling indiscriminately in neurons (both inhibi-
tory and excitatory) and glia. However, one must keep in
mind the widespread and varied expression of notch re-
ceptors and ligands. What will be the effect of a systemic
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notch plays a key role in stem cell renewal? For example,
hippocampus neurogenesis, that plays a key role in
memory, will be also inhibited by notch inhibition.
Limitations of this study
The notch family includes 4 receptors with different func-
tions. DAPT is a non-specific inhibitor of notch receptors.
Therefore the study does not specify which notch recep-
tor(s) are involved in allodynia. Moreover, Jagged 1 is also
a non-specific ligand of notch receptors. Moreover, Jagged
1 may have different affinities for different notch recep-
tors. Also, the extracellular Jagged 1 peptide will activate
notch signaling indiscriminately in neurons (both inhibi-
tory and excitatory) and glia. Moreover, the roles of notch
signaling pathway in thermal or cold allodynia of neuro-
pathic pain are still further studied. In addition, its roles in
inflammatory pain are unclear. The underlying mecha-
nisms are also the future research direction.
Conclusion
In conclusion, notch signaling activation might contrib-
ute to the development of neuropathic pain. This study
might provide a new therapeutic target for neuropathic
pain.
Key message
1. Notch signaling in spinal dorsal horn is activated in
neuropathic pain.
2. Early inhibition of notch signaling pathway prevents
the mechanical allodynia in neuropathic pain.
3. Late inhibition of notch signaling pathway reverses
the mechanical allodynia in neuropathic pain.
4. Notch signaling activation induces the mechanical
allodynia in normal animals.
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